ICH Project ICH6 to be held
November 21, 2003
About 1,850 people attended ICH6 and all days were completed.
ICH6 was held at the Osaka International Convention Center in Nakanoshima, Kita-ku, Osaka City for four days from November 12 to 15 under the theme of "New Horizons and Future Challenges. The event was attended by about 1,850 people from 44 countries and about 300 people from four exhibiting countries.
On the first day, a symposium on "Partnerships in Harmonisation" was held as a satellite session between the Global Cooperation Group (GCG) and non-ICH regions, with presentations by representatives of SADC, PANDRH, APEC, ASEAN, and other non-ICH regions, The symposium was entitled "Partnerships in Harmonisation" and included reports from representatives of SADC, PANDRH, APEC, ASEAN and other non-ICH regions. The MedDRA Users' Group also met, and a workshop on Gene Therapy as a new technology discussed technical issues and problems in clinical trials.
On the second day, the opening plenary session was held, with a welcome speech by Mr. Mori, Vice Minister of Health, Labour and Welfare, followed by a presentation on "New Era of Drug Discovery and Key Issues for Pharmaceutical Industry" by Dr. Nagayama, President of the Pharmaceutical Manufacturers Association of Japan, representing the host country. He stated that Japan is striving to improve the infrastructure for pharmaceutical R&D, particularly the clinical trial environment, as a matter of urgency, and to realize efficient and high-quality clinical trials. In Japan, there is a full-fledged movement to promote life science and biotechnology as strategic national science and technology. We must continue our efforts to create innovative new drugs and deliver them to patients around the world. He emphasized that we must continue our efforts to create innovative new drugs and bring them to patients around the world.
Mr. Nagayama, President of the Pharmaceutical Manufacturers Association of Japan (PMAJ), speaking at the closing plenary session.
Dr. Lumpkin of FDA, Dr. Krall of PhRMA, Dr. Weissenverg of EU, and Prof. Herrling of EFPIA, representing each party of ICH, gave a presentation on international regulatory harmonization efforts from the perspective of innovation in drug development. The third day of the conference was dedicated to a topic breakout session.
On the third day, there was a Topic Breakout Session, which consisted of presentations and discussions on topics discussed and agreed upon at the Expert Meeting and Steering Committee Meeting held in Osaka prior to ICH6.
The closing plenary session was held on the 15th, the last day of the meeting, and included a summary of the ICH GCG and a discussion on the future of ICH as well as future challenges and predictions for drug development in the future due to the emergence of new technologies. ICH6 ended on a high note, with the participants confirming that ICH will continue to occupy an important position in the future, as new technologies will make international collaboration even more necessary.
The End
Closing Plenary Session